Inhalation Sciences receives new order worth 60,000 Euro from long-term big pharma client

Inhalation Sciences AB (ISAB) has received a purchase order worth 60,000 EURO (almost 700,000 SEK) from a returning customer – one of the world’s top five generics companies by revenue. The client uses an ISAB PreciseInhale® aerosol generation system in-house as a central part of its R&D on inhaled pharmaceuticals.

The order is for essential spare parts and consumables for the client’s PreciseInhale® system. The client is a long-term customer of ISAB’s with a world-class generics pipeline and robust R&D organisation. Prior to its purchase and installation of PreciseInhale® the client carried out extensive contract research projects with ISAB and also has DissolvIt®, ISAB’s in vitro lung simulation module, installed in-house.

ISAB CEO Manoush Masarrat: “we are proud that PreciseInhale® is such a highly -valued and essential part of our customer’s work – delivering outstanding data and value in a range of projects. When a customer of this calibre returns, it reconfirms the unique benefits and capabilities of the system”.

Read more about PreciseInhale® here

PreciseInhale®' is ISAB’s aerosol generation system that generates exceptionally precise PK lung data from the preclinical to the clinical stages of inhaled drug development. By delivering precise and predictive data early on, PreciseInhale significantly®' reduces risk, costs and ultimately attrition in the later clinical stages of drug development.

For more information on Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.masarrat@inhalation.se Mobile: +46 (0)73 628 9153